Page 14 - Processa Pharmaceuticals News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Equities analysts predict that Processa Pharmaceuticals, Inc. (NASDAQ:PCSA – Get Rating) will report earnings of ($0.24) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Processa Pharmaceuticals’ earnings. Processa Pharmaceuticals reported earnings per share of ($0.14) during the same quarter last year, which suggests a negative year […]

05.05.2022 - HANOVER, MD, May 05, 2022 (GLOBE NEWSWIRE) - Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need ...

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA – Get Rating) was the target of a large decrease in short interest in March. As of March 31st, there was short interest totalling 79,600 shares, a decrease of 21.2% from the March 15th total of 101,000 shares. Currently, 0.7% of the shares of the company are sold short. Based on […]

Zacks Investment Research upgraded shares of Processa Pharmaceuticals (NASDAQ:PCSA – Get Rating) from a sell rating to a hold rating in a report released on Wednesday, Zacks.com reports. According to Zacks, “Processa Pharmaceuticals, Inc. is focused on the development of drug products which intended to improve the survival and/or quality of life for patients who […]

Wall Street brokerages expect Processa Pharmaceuticals, Inc. (NASDAQ:PCSA – Get Rating) to post earnings per share of ($0.18) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Processa Pharmaceuticals’ earnings. Processa Pharmaceuticals reported earnings of ($0.90) per share in the same quarter last year, which indicates a positive year-over-year […]